Nephrol Dial Transplant (2001) 16: 307-312
© 2001 European Renal Association-European Dialysis and Transplant Association
Beneficial influence of recombinant human erythropoietin therapy on the rate of progression of chronic renal failure in predialysis patients
Department of Nephrology and INSERM U 507, Necker Hospital, Paris, France
Background. Partial correction of anaemia with recombinant human erythropoietin (rHuEpo) has been shown to markedly improve the general condition and quality of life of predialysis patients, but the effects of rHuEpo therapy on blood pressure and the rate of progression of chronic renal failure (CRF) are still disputed. In particular, no study evaluated the time duration until the start of maintenance dialysis in treated patients, compared to untreated predialysis patients.
Methods. We retrospectively evaluated the rate of decline of creatinine clearance (
Ccr) and the duration of the predialysis period in 20 patients with advanced CRF treated with rHuEpo (Epo+ group), and in 43 patients with a similar degree of CRF but with less marked, asymptomatic anaemia, not requiring rHuEpo therapy (Epo- group). All patients were submitted to identical clinical and laboratory surveillance. All received similar oral supplementation with B6, B9, and B12 vitamins and oral iron supplementation. Maintenance dose of subcutaneous epoetin was 54.3±16.5 U/kg/week (median dose 3300 U/week).
Results. Initial and final haemoglobin (Hb) levels were 8.8±0.7 and 11.3±0.9 g/dl in the Epo+ group, vs 10.9±1.2 and 9.5±0.9 g/dl in the Epo- group. In the Epo+ group, Ccr declined from 0.36±0.16 during the preceding 24 months to 0.26±0.15 ml/min/ 1.73 m2/month after the start of rHuEpo therapy (P<0.05). No significant variation was observed in the Epo- group. Time duration until the start of dialysis was 16.2±11.9 in the Epo+ group, compared to 10.6±6.1 months in the Epo- group (P<0.01). Slowing of progression was observed in 10 Epo+ patients, whereas no significant variation in Ccr occurred in the other 10. There was no difference in previous Ccr rate, nor in Hb or blood pressure levels while on rHuEpo therapy between the two subgroups.
Conclusions. Our study affords conclusive evidence that rHuEpo therapy did not result in accelerated progression of CRF in any treated predialysis patients, nor deleterious increase in blood pressure, but instead resulted in significant slowing of progression and substantial retardation of maintenance dialysis. Such encouraging results remain to be validated in a large prospective, randomized study.
Keywords: chronic renal failure; predialysis; progression; recombinant erythropoietin; retardation of dialysis
Correspondence and offprint requests to: Professor Paul Jungers MD, Department of Nephrology, Necker Hospital, 149, rue de Sèvres, F-75015 Paris, France.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B. B. Newsome, S. J. Onufrak, D. G. Warnock, and W. M. McClellan Exploration of anaemia as a progression factor in African Americans with cardiovascular disease Nephrol. Dial. Transplant., November 1, 2009; 24(11): 3404 - 3411. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. E. Pergola, G. Gartenberg, M. Fu, M. Wolfson, S. Rao, and P. Bowers A Randomized Controlled Study of Weekly and Biweekly Dosing of Epoetin Alfa in CKD Patients With Anemia Clin. J. Am. Soc. Nephrol., November 1, 2009; 4(11): 1731 - 1740. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Tomasello Anemia of Chronic Kidney Disease Journal of Pharmacy Practice, June 1, 2008; 21(3): 181 - 195. [Abstract] [PDF]
|
|
|
|
|
|
Y. Furumatsu, Y. Nagasawa, T. Hamano, H. Iwatani, K. Iio, T. Shoji, T. Ito, Y. Tsubakihara, and E. Imai Integrated therapies including erythropoietin decrease the incidence of dialysis: lessons from mapping the incidence of end-stage renal disease in Japan Nephrol. Dial. Transplant., March 1, 2008; 23(3): 984 - 990. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. W Maddux, S. Shetty, M. A del Aguila, M. A Nelson, and B. M Murray Effect of Erythropoiesis-Stimulating Agents on Healthcare Utilization, Costs, and Outcomes in Chronic Kidney Disease Ann. Pharmacother., November 1, 2007; 41(11): 1761 - 1769. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. C. Dowling Prevalence, etiology, and consequences of anemia and clinical and economic benefits of anemia correction in patients with chronic kidney disease: An overview Am. J. Health Syst. Pharm., July 1, 2007; 64(13_Supplement_8): S3 - S7. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Benz, R. Schmidt, K. Kelly, and M. Wolfson Epoetin Alfa Once Every 2 Weeks Is Effective for Initiation of Treatment of Anemia of Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., March 1, 2007; 2(2): 215 - 221. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Lefebvre, M. S. Duh, S. Buteau, B. Bookhart, and S. H. Mody Medical Costs of Untreated Anemia in Elderly Patients with Predialysis Chronic Kidney Disease J. Am. Soc. Nephrol., December 1, 2006; 17(12): 3497 - 3502. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Germain, C. V. Ram, S. Bhaduri, K. L. Tang, M. Klausner, and M. Curzi Extended epoetin alfa dosing in chronic kidney disease patients: a retrospective review Nephrol. Dial. Transplant., October 1, 2005; 20(10): 2146 - 2152. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. H. Henry, P. Bowers, M. T. Romano, and R. Provenzano Epoetin Alfa: Clinical Evolution of a Pleiotropic Cytokine Arch Intern Med, February 9, 2004; 164(3): 262 - 276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. F. Griffith, D. N. Reddan, P. S. Klassen, and W. F. Owen Left ventricular hypertrophy: a surrogate end point or correlate of cardiovascular events in kidney disease? Nephrol. Dial. Transplant., December 1, 2003; 18(12): 2479 - 2482. [Full Text] [PDF]
|
|
|
|
 |
|
 T Ng, G Marx, T Littlewood, and I Macdougall Recombinant erythropoietin in clinical practice Postgrad. Med. J., July 1, 2003; 79(933): 367 - 376. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Rossert, B. Fouqueray, and J. J. Boffa Anemia Management and the Delay of Chronic Renal Failure Progression J. Am. Soc. Nephrol., July 1, 2003; 14(90002): S173 - 177. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Collins Anaemia management prior to dialysis: cardiovascular and cost-benefit observations Nephrol. Dial. Transplant., June 1, 2003; 18(suppl_2): ii2 - ii6. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. C. Macdougall CREATE: new strategies for early anaemia management in renal insufficiency Nephrol. Dial. Transplant., June 1, 2003; 18(suppl_2): ii13 - ii16. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Silverberg, D. Wexler, M. Blum, J. Z. Tchebiner, D. Sheps, G. Keren, D. Schwartz, R. Baruch, T. Yachnin, M. Shaked, et al. The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron Nephrol. Dial. Transplant., January 1, 2003; 18(1): 141 - 146. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.-Y. Jungers, C. Robino, G. Choukroun, T. Nguyen-Khoa, Z. A. Massy, and P. Jungers Incidence of anaemia, and use of epoetin therapy in pre-dialysis patients: a prospective study in 403 patients Nephrol. Dial. Transplant., September 1, 2002; 17(9): 1621 - 1627. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. N. Becker, Y. T. Becker, G. E. Leverson, and D. M. Heisey Erythropoietin therapy may retard progression in chronic renal transplant dysfunction Nephrol. Dial. Transplant., September 1, 2002; 17(9): 1667 - 1673. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Gupta Does iron depletion induced by erythropoietin slow the progression of chronic kidney disease? Nephrol. Dial. Transplant., January 1, 2002; 17(1): 175 - 176. [Full Text]
|
|